Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value |
|---|
| Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
VR VRTX VERTEX PHARMACEUTICALS INC / MA FY ended Feb 06, 2026 | $541.69 | $137.30B | $134.75B | $12.00B | $4.88B | $3.95B | 35.36x | 11.44x | 27.38x |
AL ALNY ALNYLAM PHARMACEUTICALS, INC. FY ended Feb 06, 2026 | $237.10 | $31.73B | $33.03B | $3.71B | $499.17M | $313.75M | 101.76x | 8.54x | 46.01x |
SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $20.86 | $2.20B | $2.78B | $2.20B | -$686.34M | -$713.41M | -2.93x | 1.00x | — |
RG RGNX REGENXBIO Inc. FY ended Feb 27, 2026 | $9.66 | $637.69M | $690.20M | $170.44M | -$187.17M | -$193.88M | -2.57x | 3.74x | — |
IO IONS IONIS PHARMACEUTICALS INC FY ended Feb 19, 2026 | $61.05 | $10.15B | $10.29B | $943.71M | -$349.89M | -$381.39M | -25.65x | 10.75x | — |
PT PTCT PTC THERAPEUTICS, INC. FY ended Feb 18, 2026 | $70.09 | $5.85B | $6.35B | $1.73B | $741.26M | $682.64M | 9.01x | 3.38x | 8.46x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 27.91x | 3/6 | $17.61B | $90.96 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 6.48x | 6/6 | $20.86B | $107.77 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 19.16x | 6/6 | $6.69B | $34.54 | Included in the active peer mix. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
VR VRTX VERTEX PHARMACEUTICALS INC / MA FY ended Feb 06, 2026 | $541.69 | $137.30B | $134.75B | $12.00B | $4.88B | $3.95B | 35.36x | 11.44x | 27.38x |
AL ALNY ALNYLAM PHARMACEUTICALS, INC. FY ended Feb 06, 2026 | $237.10 | $31.73B | $33.03B | $3.71B | $499.17M | $313.75M | 101.76x | 8.54x | 46.01x |
SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $20.86 | $2.20B | $2.78B | $2.20B | -$686.34M | -$713.41M | -2.93x | 1.00x | — |
RG RGNX REGENXBIO Inc. FY ended Feb 27, 2026 | $9.66 | $637.69M | $690.20M | $170.44M | -$187.17M | -$193.88M | -2.57x | 3.74x | — |
IO IONS IONIS PHARMACEUTICALS INC FY ended Feb 19, 2026 | $61.05 | $10.15B | $10.29B | $943.71M | -$349.89M | -$381.39M | -25.65x | 10.75x | — |
PT PTCT PTC THERAPEUTICS, INC. FY ended Feb 18, 2026 | $70.09 | $5.85B | $6.35B | $1.73B | $741.26M | $682.64M | 9.01x | 3.38x | 8.46x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 27.91x | 3/6 | $17.61B | $90.96 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 6.48x | 6/6 | $20.86B | $107.77 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 19.16x | 6/6 | $6.69B | $34.54 | Included in the active peer mix. |
